Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
north, now CDIO is up .65 or and 65% on the day. Volume is 10X average daily volume w 3 hours left in trading.
RMB, someone needs to grab Nissen by the scruff of the neck and lead him to water and make him drink if you catch my drift.
Chrom, thanks for that good info.
It would be interesting to know what is pushing the little spike this morning. Sitting at the 50 DMA on a nice 8.5% gain for the day. Is it the Eddingpharm news? Very little shares moving but positive for now.
Skipperdog11, I agree with the Docs advising eating more fish. That has been discussed many times here in the past about how much fish an individual would have to eat to get enough fish oil to provide any benefit. It's just that fish is probably better than some of the other meats we eat.
Ironically I was watching Mountain Men the other day and one of these individuals went fishing to catch 10-15 large walleye. He then boiled the fish and scooped off the unrefined fish oil. His yield was approximately 1 cup of unpurified fish oil which had a strong smell and he used to put on his bait on his traps to help lure the prey. So I laughed and thought about the generics being an inferior product to V.
gozips, thanks for this good news. It's one of many open items that need to be checked off to gain more V scripts.
marjac, hope everything overall is going well for you. Always good to see you post with legal information. GL
BBI, thanks. I think we all agree that communications from Amarin are pathetic to say the least. I recall posting (after Duaster) that SP was down over 70% and ironically Press Releases were also down that same 70+%. If they would hire a public relations / marketing team to focus strictly on messaging, the world would gain attention and scripts would grow. All the opportunities they have squandered when there are so many positives, i.e., SOC for AHA and ADA. (Diabetes) and more.
BBI, thanks for the reminders however painful they have been. A question to you and / or the board, most or all of them occurred under JT or KM and the old board. Do you think that maybe under AD, Holt and the new board that maybe we can see something more promising than we have seen in the past? TIA
MRM, and if you attribute the sp uptick today to a rising tide with the overall Nasdaq, we can see the Nasdaq at ~$27,000 at the end of your 39 days. :)
BBI, you are correct in that Amarin does a PP job of educating the doctors about V. Raf, CaptBeer and others have done a lot through X and other means but crickets from Amarin. I don't understand why they don't hire a public relations / marketing team to blitz the medical community and the masses. Denner and his team surely see that and should be doing something proactive to target the potential influencers. Millions of companies put out press releases that I don't see as I am not looking for them. Amarin is and has been in the insanity mode. Same nothing sh!! and hoping for a better outcome.
None. Nice to see the SP making a nice positive movement this AM. Reading through the posts regarding the revenue and inventory issues, I haven't ran any pro formas, but wouldn't it make sense to lower pricing to compete better with generics and avoid having to write-off the inventory? If Amarin just wrote off $5M Q3 and $9M in Q2 and as everyone knows, we need Revenue or WS will not take an interest in the stock. Everyone knows you can't cut your way to success as there is a point there is nothing left to give and it will be impossible to climb back up. Any thoughts?
RMB, I agree with your comments. At this point just crying in my wine but can't afford the nice fruit / cheese platter to enjoy it with. Who would have known it would be such a disappointment to this date. Still holding long for a turnaround and sell to BP.
Canes, I agree with what you say. IF Kennedy and JT had done their job none of us on this board would even know Miranda Du. All the what if's you state are accurate but would not have been necessary as our case would have prevailed in other jurisdictions. And I would not be here reading the posts as the stock price would be much higher and / or owned by BP. However, here we are. The future is the only thing we can hope improves.
Thanks Capt. Not the revenue increase we would like to see but the US will be a slower trudge unless we get some positive Mitigate or Brave outcomes.
Capt, in trying to gain insight as to Q3 revenue, did we determine at what point during Q2 did the pricing go down to give us the reduced revenue for Q2 so we can better determine how Q3 revenue will shake out? Or, if the price for script toward the latter part of Q2 that can be used to calculate Q3 revenue?
I know we were surprised (disappointed) to learn at the Q2 ER that even with increased scripts, the revenue was down due to the reduced pricing per script.
Jas, I personally would like to also see a thumb down option for those posts that are one disagrees with.
JRoon, it certainly seems to me that prior management failed us. Now as far as Denner, I concur that the jury is still out. It has been quiet and we can only speculate that Denner's statement that Amarin was undervalued is true and the SP begins to improve.
I have too much invested to walk away from it at this point.
GLTA longs.
JRoon, the difference in my opinion is that prior management couldn't find their ass when blindfolded. They did little to fight generics infringement. They should have under JT, join the Marjac case to provide standing. They should have this, they should have that;;; But they didn't!!! Water under the bridge.
Hopefully AD and the new board will be proactive to take steps necessary to open all opportunities and get this sold to BP.
JMO
JRoon71, I'm curious as to your today's comments regarding share buy-back. I floated that idea on Post 411793 for Sarissa purchases and a share buy-back and your reponse on Post 411798 was against a share buy-back. SP was ~#1.17 versus today's $.92 but am curious as to what has changed in your thought process. Again, my position has not changed;
Improved (positive) ER
EU scripts ramping
Sarissa purchasing more shares (above the 4.1M)
Buyback of shares (up to 50M)
TIA
Content is good, but IMO by far a better speaker than JT or KM.
shadolane, I pray that next weeks Cantor Healthcare conference will reveal something positive about the future of Amarin that will drive the SP north of $1.00. It seems that any good news is followed by a small uptick and then shorted back down. Lesson learned by me about how a stock price can be manipulated within a range. I don't expect a reverse split but I seem to never accurately anticipate the movement. GLTA
Kiwi, thanks. I couldn't remember the exact number. But we can all agree that the addressable market is quite large.
JR, since he spent $100M on Amarin, I think he should focus some time on this one. Just sayin. And maybe he is but as we are all aware they are quieter than prior management which was church mouse quiet.
CaptBeer, thanks for the numbers. BTW, didn't someone post over the weekend that EU has 475,000,000 people on statins that could qualify for Vascepa. If so, the big question is how many and when can those patients be put on V. I have learned since purchasing AMRN prior to the ADCOM, through the Dusaster, piss poor management ( not addressing the cropped tables and not getting involved in the marvelous Marjac filings), that this has certainly been a tough row to hoe. Hopefully AD and the new board can make some positive changes, however, it has certainly been quieter than I would like to have.
Going back to the ~475,000,000 addressable patient market, I guess the biggest question is how much of that market Amarin can hope to gain. Or when will BP realize that they can capitalize on that market and start making offers. If AMRN can get 10% of that market in two years that would be huge. What is the average country pay rate for V? $185 / Mo.?
Stay tuned as the AMRN world churns.
CaptBeer, thanks again for the numbers. Always appreciate all you do for this board. I pray that some day all of this will take a very positive turn and we can tyake advantage and move on.
Nuke, didn't read through the article but your reference to 'we hold a ticking timebomb'. Is that supposed to be a good or a bad thing.
TIA
Wolf, see CaptBeer's Post 414601 from Friday.
Yes. I play golf with his dad 3 times a week. The son is a real trooper but not able to get out for much golf recently as the 100 degree plus temps and effects of treatment taking tolls on him.
Thanks for asking.
What, you do seem to have some medical knowledge due to your life experiences and your wife's job, but some of your posts come off as an arrogant and condescending A$$. JMO Have a nice day.
JRoon71, this may have already been responded to, but previously we were under the impression that Sarissa sold the shares and the other companies purchased them. This was to allow Sarrisa to report a tax loss. Of course the other companies in the Sarissa family now own the stock at the higher cost basis I think in the Nov / Dec timeframe if memory serves. Denner reported out that Sarissa still owed the 24 - 25 M shares.
I am not certain if the other companies you mentioned would have to report additional purchases but I would assume they would as they are Sarissa companies.
Nuke, thanks for your candid but humane answer. Unfortunately I think it is at the point of making the absolute best of the limited time left. For those of you that believe in prayer, please say a prayer for Jack, a 36 year old young man from the Houston area.
Zip, thanks for the information. I will pass this on to his father that I play golf with.
CBB, thanks for the info. I will pass it on.
I'm looking for any response to the following real situation. A young man 36 years of age has cancer/s. One, (I don't recall the name) is a very rare cancer and is being treated through chemo (oral Votrient). The other issue is that he has tumors in his back that has to be treated by radiation. Situation declining and recently started a unique vitamin/medicine regimen (not FDA approved) but has shown some progress in various cancer patients. This drug is fenbendazole and is used by veternarians as a dewormer. The overall prospect is not good but I wanted to see what the thoughts of people on this board as to how much Vascepa might help with the inflammation and overall benefit. I'm sure it would help.
Let me know your thoughts on this. TIA.
Capt, thanks for the information. It certainly will be exciting to see the growth play out to give us a sense of acceptance of V.
JRoon71, yes that's what I am thinking by getting past the initial inertia. The train is moving now and a hockey stick ramp would help and I believe it is possible. Execution and educating the medical communicty is critical at this point.
Tats, thanks. That's what I thought. Now from a positive perspective, just ramping up, is 19% something to be excited about? If we can get past the initial inertia and see incremental 19% + every month and then add more countries, I'll say it's positive growth.
shadolane, I don't know the validity of your numbers as I don't know where they are being pulled. It does seem high as the Q2 results should have been better if we were getting scripts like that from Europe. I seem to recall previously that some numbers reported were actually pill count which then would your numbers be divided by 120 ?
CaptBeer might shed some light on this.
situ, if in fact those numbers are correct that seems like a nice 19% increase in Vazkepa scripts Month over Month.